Navigation Links
iBio Adds New Therapeutic Antibody to Its Pipeline
Date:3/4/2013

eins difficult or impossible to produce with other methods; broad applicability to biologics, including therapeutic proteins and vaccines; production time measured in weeks instead of months or more. Additional benefits may include a surge capacity for remedial action against bioterrorism and pandemic disease including influenza; product entry that is unconstrained by traditional process patents, and significantly lower capital and operating costs for comparable production.

About Influenza

Influenza virus infection is a common infectious disease that often causes mild symptoms but can lead to severe symptoms and death. Influenza epidemics occur yearly, causing three to five million cases of severe illness, and about 250,000 to 500,000 deaths worldwide. Although the common strains of influenza constitute a significant public health concern, more dangerous influenza strains have emerged periodically leading to pandemics that kill millions of people. The high mutation rate of influenza viruses leads to the frequent emergence of new strains and also to the development of resistance to antiviral drugs. An effective antibody-based influenza drug based on iBio technology has the potential to effectively treat such drug-resistant infections as well as complex and advanced infections.

About Antibody Therapeutics

The use of monoclonal antibodies for the treatment of a wide variety of diseases and illnesses has emerged as one of the most important contributions of biotechnology to clinical medicine. A few dozen antibody products generate global annual sales of about $50 billion, and several hundred new product candidates are in clinical trials for many medical applications. Rituximab is an antibody drug approved for treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other diseases, generating annual sales in excess of $6 billion. Palivizumab is an antibody drug used to prevent serious lung infections caused
'/>"/>

SOURCE iBio, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Comprehensive Global Testing Solutions for Novel Hepatitis C Therapeutics, New Webinar Hosted by Xtalks
2. United Therapeutics Corporation To Announce Fourth Quarter And Annual 2012 Financial Results Before Market Open On Tuesday, February 26, 2013
3. Society for Brain Mapping and Therapeutics endorse President Obamas support for Human Brain Mapping research; nominating him for prestigious Pioneer in Healthcare Policy Award
4. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
5. United Therapeutics Announces Additional $420 Million Share Repurchase Program
6. Juventas Therapeutics Hires Biotechnology Veteran Paul Resnick as Vice President of Business Development
7. Convoy Therapeutics Announces the Relaunch of Their Interactive Website
8. Exon skipping to restore gene expression is promising therapeutic strategy for muscular dystrophy
9. Shield Therapeutics Selects OpenClinica Enterprise
10. Regenetek Research Inc. Launches New Intelligent Software for Therapeutic Stem Cell Trials
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... LOUIS , Dec. 23, 2014 ... today that the waiting period under the Hart-Scott-Rodino ... the acquisition expired on December 22, 2014, thereby ... review requirement for the acquisition of the Company ... U.S. antitrust clearance satisfies another condition to closing ...
(Date:12/22/2014)... 22, 2014   Synthetic Biologics, Inc. ... pathogen-specific therapies for serious infections and diseases, ... today announced positive topline safety and tolerability ... of SYN-004, the Company,s investigational oral beta-lactamase ... difficile (C. difficile) infection, antibiotic-associated diarrhea ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) ... an online medical bill review and advocacy service, has ... the FREE WellCard Savings discount health services marketplace. ... that was more than they expected to pay. As ... health care costs, WellCard Savings is pleased to offer ...
(Date:12/19/2014)... 19, 2014 Bioject Medical Technologies ... manufacturer of needle-free injection technology, today announced that ... Therapeutics, Inc. (“ITI”) for ITI to use the ... LAMP™ vaccine platform. , In the agreement, ... license to the Biojector®-2000 that triggers based on ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... , , , ALBANY, Ore., ... financial results for the first quarter of fiscal 2010, which ended ... a 5% decrease compared to revenue of $4.9 million in the ... quarter was $1.0 million, compared to operating income of $314,000 for ...
... Md., Aug. 6 GenVec, Inc. (Nasdaq: GNVC ) today ... , , (Logo: http://www.newscom.com/cgi-bin/prnh/20081205/DC50112LOGO ... net loss of $4.8 million ($0.05 per share) for the three months ... ($0.08 per share) in the comparable quarter of 2008. For the six ...
... 6 Novavax, Inc. (Nasdaq: NVAX ) announced ... Chief Financial Officer and treasurer. Mr. Driscoll will report ... , , Previously Mr. Driscoll served as ... Genelabs Technologies, Inc. Prior to his position at Genelabs, ...
Cached Biology Technology:Synthetech Reports First Quarter Fiscal 2010 Results 2Synthetech Reports First Quarter Fiscal 2010 Results 3Synthetech Reports First Quarter Fiscal 2010 Results 4Synthetech Reports First Quarter Fiscal 2010 Results 5Synthetech Reports First Quarter Fiscal 2010 Results 6GenVec Reports Second Quarter 2009 Financial Results 2GenVec Reports Second Quarter 2009 Financial Results 3GenVec Reports Second Quarter 2009 Financial Results 4GenVec Reports Second Quarter 2009 Financial Results 5GenVec Reports Second Quarter 2009 Financial Results 6GenVec Reports Second Quarter 2009 Financial Results 7Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer 2
(Date:12/17/2014)... , Dec. 16, 2014  Automation is ... this more evident than at international borders. Over ... document scanners have allowed veteran travelers to self ... Passport Control (APC) Kiosks at an increasing number ... globe. According to Maxine ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
(Date:12/10/2014)... Forest Baptist Medical Center today announced plans for a ... Funding for this $50 million capital project is part ... launched next summer. The medical education ... R.J. Reynolds Tobacco Company complex, adjacent to 525@vine in ... plans to be ready to welcome medical students in ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4
... consider giving thanks for the bacteria-busting ability of cranberry ... beverage holds important clues for preventing cavities. , ... D.D.S., Ph.D., at the University of Rochester Medical Center ... juice a powerful weapon against bladder infections also hold ...
... : It makes me sad when an article that should ... webpage of the student's group in the iGEM competition , ... for their bacterial 'camera'. , Using Petri dishes full ... at The University of Texas at Austin and UCSF successfully ...
... College of Medicine and the German Cancer Research Institute ... regions of a cell--a process crucial for the cellular ... metastasis. Their study appears in the November 24 issue ... Singer and Dr Stefan Huettelmaier, the research team focused ...
Cached Biology News:Give thanks for the cranberry, say dental researchers 2Give thanks for the cranberry, say dental researchers 3Student scientists create living bacterial photographs 2Student scientists create living bacterial photographs 3Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell 2
Anti Autotaxin /ENPP2 , - (Rabbit)...
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
Biology Products: